Navigation Links
MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology

'A Highly Efficient, Clinical Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor Capacity'

GAITHERSBURG, Md., Dec. 4 /PRNewswire/ --MaxCyte, Inc., a clinical-stage therapeutics company and pioneer in clinical scale, non-viral cell loading systems, announces that Joseph C. Fratantoni, MD, Vice President Medical Affairs and Clinical Development at MaxCyte, will give a presentation on a breakthrough approach to developing cancer therapies at the 50th ASH Annual Meeting to be held at the Moscone Center in San Francisco, December 6-9, 2008. Dr. Fratantoni's presentation is entitled, "A Highly Efficient, Clinically Applicable Transfection Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor Capacity" and will be held during the Tumor Immunotherapy Poster II Session on Monday, December 8, 2008 at 5:30 PM - 7:30 PM in Moscone Center, Hall A (Poster Board no.: III-976).

The presentation will discuss how chimeric tumor-antigen receptor mRNA loaded peripheral blood mononuclear cells offer the potential to develop customizable, engineered outpatient transfusion medicine products for cancer therapies without the infrastructure and logistical challenges associated with development of traditional cellular therapy products. This represents a paradigm shift in current cancer therapy approaches and utilizes current transfusion medicine infrastructure present in any major hospital.

About MaxCyte

MaxCyte is the leader in providing clinical/commercial cell modification technologies and unparalleled expertise to the global leaders in cell-based therapies. MaxCyte's cell transfection technology platform

enables the discovery, development, manufacturing and delivery of innovative and important therapeutic products for a wide range of diseases.

MaxCyte's licenses its cell modification technology to companies developing cell-based therapies and sells instruments and disposables to leading biopharmaceutical companies for drug discovery. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of Chronic Lymphocytic Leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition, MaxCyte's partner in Japan has commercially launched an immunotherapy cancer service. More than a dozen commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER). Building on its core technology and relationships, new opportunities are being pursued in the development of first-in-class targeted therapies for cancer, autoimmune, and infectious diseases. MaxCyte intends to develop these programs to the proof-of-concept stage and then enter into co-development agreements with biopharmaceutical companies.

For more information, visit

SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MaxCyte to Present at the Phacilitate Cell and Gene Therapy Forum 2008
2. MaxCyte to Present at the BIO CEO & Investor Conference
3. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
5. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
6. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
7. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
8. AtriCure to Present at Roth Capital Partners 2007 New York Conference
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. MDS to Present at Thomas Weisel Partners Healthcare Conference
11. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
Post Your Comments:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: